Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ELOXD NASDAQ:KZIA NASDAQ:LPCN NYSEAMERICAN:VNRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeELOXDEloxx Pharmaceuticals$6.20$2.18$0.00▼$10.00$2.85M-1932.884,013 shs1,048 shsKZIANovogen$11.72+6.6%$11.24$4.86▼$17.40$19.37M2.17220,825 shs45,569 shsLPCNLipocine$2.11+2.7%$2.84$1.81▼$12.37$17.35M0.48286,441 shs12,790 shsVNRXVolitionRX$1.39-22.2%$2.90$1.43▼$18.80$12.02M1.04426,798 shs440,422 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceELOXDEloxx Pharmaceuticals0.00%+52.33%+333.23%+563,536.36%+563,536.36%KZIANovogen0.00%-14.01%-23.89%+33.70%+94.51%LPCNLipocine0.00%-8.89%-13.50%-73.98%-34.71%VNRXVolitionRX0.00%-32.96%-20.44%-55.21%-83.84%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeELOXDEloxx Pharmaceuticals$6.20$2.18$0.00▼$10.00$2.85M-1932.884,013 shs1,048 shsKZIANovogen$11.72+6.6%$11.24$4.86▼$17.40$19.37M2.17220,825 shs45,569 shsLPCNLipocine$2.11+2.7%$2.84$1.81▼$12.37$17.35M0.48286,441 shs12,790 shsVNRXVolitionRX$1.39-22.2%$2.90$1.43▼$18.80$12.02M1.04426,798 shs440,422 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceELOXDEloxx Pharmaceuticals0.00%+52.33%+333.23%+563,536.36%+563,536.36%KZIANovogen0.00%-14.01%-23.89%+33.70%+94.51%LPCNLipocine0.00%-8.89%-13.50%-73.98%-34.71%VNRXVolitionRX0.00%-32.96%-20.44%-55.21%-83.84%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceELOXDEloxx Pharmaceuticals 0.00N/AN/AN/AKZIANovogen 2.50Moderate Buy$21.0079.18% UpsideLPCNLipocine 2.33Hold$15.00612.59% UpsideVNRXVolitionRX 2.50Moderate Buy$46.673,250.08% UpsideCurrent Analyst Ratings BreakdownLatest ELOXD, KZIA, LPCN, and VNRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2026VNRXVolitionRX BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold4/21/2026KZIANovogen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026VNRXVolitionRX CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold4/20/2026VNRXVolitionRX D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Hold4/15/2026KZIANovogen LaidlawSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$25.004/6/2026LPCNLipocine HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral4/2/2026VNRXVolitionRX HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$30.00 ➝ $20.003/27/2026LPCNLipocine Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/26/2026VNRXVolitionRX D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$60.003/18/2026VNRXVolitionRX D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$60.00(Data available from 6/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookELOXDEloxx Pharmaceuticals$6.36M0.45N/AN/A($85.17) per share-0.07KZIANovogen$42K461.27N/AN/A($5.34) per share-2.19LPCNLipocine$1.98M8.76N/AN/A$2.61 per share0.81VNRXVolitionRX$1.73M6.95N/AN/A($5.30) per share-0.26Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateELOXDEloxx Pharmaceuticals-$5.99MN/AN/AN/AN/AN/AN/AN/A8/10/2026 (Estimated)KZIANovogen-$13.41MN/AN/AN/AN/AN/AN/AN/AN/ALPCNLipocine-$9.63M-$1.88N/AN/AN/A-571.18%-66.70%-59.39%8/4/2026 (Estimated)VNRXVolitionRX-$23.36M-$0.56N/AN/AN/A-997.49%N/A-289.87%8/13/2026 (Estimated)Latest ELOXD, KZIA, LPCN, and VNRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026VNRXVolitionRX-$0.70-$0.97-$0.27-$0.97$1.52 million$0.99 million5/7/2026Q1 2026LPCNLipocine-$0.51-$0.54-$0.03-$0.54$0.16 million$0.12 million3/19/2026Q2 2026KZIANovogenN/A-$1.34N/A-$1.34N/AN/A3/10/2026Q4 2025LPCNLipocine-$0.60-$0.34+$0.26-$0.34$0.12 million$1.15 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthELOXDEloxx PharmaceuticalsN/AN/AN/AN/AN/AKZIANovogenN/AN/AN/AN/AN/ALPCNLipocineN/AN/AN/AN/AN/AVNRXVolitionRXN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioELOXDEloxx PharmaceuticalsN/A0.530.53KZIANovogenN/A2.87N/ALPCNLipocineN/A9.999.99VNRXVolitionRXN/A0.330.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipELOXDEloxx Pharmaceuticals2.90%KZIANovogen30.89%LPCNLipocine9.11%VNRXVolitionRX8.09%Insider OwnershipCompanyInsider OwnershipELOXDEloxx Pharmaceuticals25.90%KZIANovogen1.00%LPCNLipocine6.35%VNRXVolitionRX6.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableELOXDEloxx Pharmaceuticals30460,000342,000Not OptionableKZIANovogen121.65 million1.64 millionNo DataLPCNLipocine108.24 million7.72 millionNo DataVNRXVolitionRX808.63 million8.03 millionNot OptionableELOXD, KZIA, LPCN, and VNRX HeadlinesRecent News About These CompaniesVolitionRx Announces Pricing of $4.6 Million Public OfferingJune 7 at 6:30 PM | prnewswire.comAnalysts Set VolitionRX Limited (NYSEAMERICAN:VNRX) Target Price at $46.67June 7 at 3:37 AM | americanbankingnews.comVolitionRx Files New Patent Protecting its Nu.Q® NETs Test for Ebola Triage and Treatment MonitoringJune 3, 2026 | prnewswire.comVolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable MarketsMay 27, 2026 | prnewswire.comVolitionRx Limited (VNRX): 7 Best Rated Penny Stocks to Buy According to Wall Street AnalystsMay 24, 2026 | finance.yahoo.comVolitionRX Earnings Call Balances Breakthroughs and RisksMay 20, 2026 | tipranks.comVolitionRX Ltd (VNRX) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic ...May 15, 2026 | finance.yahoo.comVolitionRX Earnings Call: Breakthrough Science, Cash Burn RiskMay 15, 2026 | tipranks.comVolitionRx Limited (VNRX) Q1 2026 Earnings Call TranscriptMay 15, 2026 | seekingalpha.comVolitionRx Limited Announces First Quarter 2026 Financial Results and Business UpdateMay 14, 2026 | prnewswire.comVolitionRx (VNRX) price target increased by 1,618.09% to 29.79May 14, 2026 | msn.comVolitionRX Ltd.May 12, 2026 | marketwatch.comVolitionRx Limited Schedules First Quarter 2026 Earnings Conference Call and Business UpdateMay 11, 2026 | prnewswire.comVolitionRx Announces Submission of Manuscript for Nu.Q® Vet Cancer Test in CatsMay 6, 2026 | prnewswire.comVolitionRx Enacts One-for-Twenty Reverse Stock SplitApril 29, 2026 | theglobeandmail.comVolition Announces Breakthrough Finger-Prick Detection of Nucleosomes; Expanding Global Market Potential for Sepsis TestingApril 29, 2026 | prnewswire.comVolitionRx (VNRX) price target decreased by 17.48% to 1.73April 28, 2026 | msn.comVNRX: Upcoming Milestones Expected in 2026; Year-End 2025 Results. Special Meeting of Stockholders Approves Reverse-Split. Subsequently, the Board of Directors authorized a 1 ...April 28, 2026 | finance.yahoo.comVolitionRx Announces Acceptance of Compliance Plan by NYSE AmericanApril 23, 2026 | prnewswire.comD Boral Capital downgrades VolitionRx (VNRX)April 21, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeELOXD, KZIA, LPCN, and VNRX Company DescriptionsEloxx Pharmaceuticals OTCMKTS:ELOXD$6.20 0.00 (0.00%) As of 06/5/2026 03:48 PM EasternEloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.Novogen NASDAQ:KZIA$11.72 +0.73 (+6.64%) As of 10:24 AM Eastern This is a fair market value price provided by Massive. Learn more.Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.Lipocine NASDAQ:LPCN$2.10 +0.06 (+2.68%) As of 10:25 AM Eastern This is a fair market value price provided by Massive. Learn more.Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.VolitionRX NYSEAMERICAN:VNRX$1.39 -0.40 (-22.18%) As of 10:25 AM Eastern This is a fair market value price provided by Massive. Learn more.VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/01 - 06/05 Samsara Just Answered The AI Question—Is Wall Street Ready To Listen? A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Meta Unveils Subscriptions: A New Offering With Real Growth Potential Five Below Down 12% Post Earnings—Is the Selloff Overdone? Petco Faces Tough Competition, But Momentum Is Building IREN's 800MW Bet Flips the AI Power Switch Buy the Dip? Broadcom's AI Moat Is Wider Than Ever Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
